Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Blau FarmaceuticaBSP:BLAU3 -1.89%87 Days Inventory is 245.44 as of Mar. 2026, which is 42% above its 10-year median of 172.73. GuruFocus rates BSP:BLAU3 with a GF Score™ of 87/100 and a GF Value™ of R$11.17 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 922 Drug Manufacturers companies, Blau Farmaceutica ranks worse than 73.86% on this metric.
The historical rank and industry rank for Blau Farmaceutica's Days Inventory or its related term are showing as below:
BSP:BLAU3'
s Days Inventory Range Over the Past 10 Years
Min: 108.64 Med: 172.73 Max: 247.71
Current: 239.61
During the past 10 years, Blau Farmaceutica's highest Days Inventory was 247.71. The lowest was 108.64. And the median was 172.73.
BSP:BLAU3's Days Inventory is ranked worse than 73.86% of 922
companies
in the Drug Manufacturers industry
Industry Median: 164.58
vs BSP:BLAU3: 239.61
Blau Farmaceutica's Days Inventory
declined
from Mar. 2025 (264.67) to Mar. 2026 (245.44).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Blau Farmaceutica's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.37.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Blau Farmaceutica's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.58.
Blau Farmaceutica (BSP:BLAU3) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Blau Farmaceutica's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Blau Farmaceutica's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Blau Farmaceutica Days Inventory Related Terms
Blau Farmaceutica Days Inventory Historical Data
* Premium members only.
The historical data trend for Blau Farmaceutica's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:BLAU3 vs ZTS, UTHR, VTRS: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Blau Farmaceutica's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blau Farmaceutica Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Blau Farmaceutica's Days Inventory distribution charts can be found below:
* The bar in red indicates where Blau Farmaceutica's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Blau Farmaceutica (BSP:BLAU3) has a Days Inventory of 245.44 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Blau Farmaceutica and its competitors. This is 42% above median its historical median of 172.73. Over the past decade, Blau Farmaceutica's Days Inventory has ranged from 108.64 to 247.71. According to the industry distribution chart, Blau Farmaceutica ranks #681 out of 922 companies in the Drug Manufacturers industry, placing it in the top 73.9%.
Is Blau Farmaceutica's Days Inventory too high?
Blau Farmaceutica's current Days Inventory of 245.44 is 42% above median its 10-year median of 172.73. Over the past 10 years, this metric has ranged from a low of 108.64 to a high of 247.71. The Drug Manufacturers industry median Days Inventory is 164.58. Blau Farmaceutica's value of 245.44 is 49.1% above this industry median. Based on the distribution chart, Blau Farmaceutica ranks #681 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Blau Farmaceutica has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Blau Farmaceutica's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Blau Farmaceutica ranks #681 out of 922 companies for Days Inventory. This places Blau Farmaceutica in the lower half of its industry. The industry median Days Inventory is 164.58. Blau Farmaceutica's value of 245.44 is 49.1% above this benchmark. Historically, Blau Farmaceutica's own Days Inventory has ranged from 108.64 to 247.71 over the past decade. While the company's 10-year median is 172.73 vs. the industry median of 164.58, Blau Farmaceutica has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.58, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Blau Farmaceutica's current Days Inventory of 245.44 is 49.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Blau Farmaceutica and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Blau Farmaceutica's current Days Inventory is 245.44, which is 42% above median its own 10-year median of 172.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Blau Farmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Blau Farmaceutica (BSP:BLAU3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$11.17, compared to a current price of R$8.81 — trading 21.1% below its estimated fair value. The current Days Inventory is 245.44, which is 42% above median its 10-year median of 172.73 and 49.1% above the Drug Manufacturers industry median of 164.58. Blau Farmaceutica's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Blau Farmaceutica (BSP:BLAU3), the current Days Inventory is 245.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Blau Farmaceutica (BSP:BLAU3) Overvalued in 2026?
Based on GuruFocus' analysis, Blau Farmaceutica stock appears to be undervalued.
The current stock price of R$8.81 is trading 21.1% below its estimated GF Value™ of R$11.17.
GuruFocus considers Blau Farmaceutica to be Modestly Undervalued.
Key valuation signals for BSP:BLAU3:
Days Inventory: 245.44 (42% above median its 10-year median of 172.73)
GF Value™: R$11.17 vs. price of R$8.81 (21.1% below fair value)
Industry Position: 49.1% above the Drug Manufacturers median (#681 of 922)
No single metric tells the full story. See the BSP:BLAU3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
87GF Score
Get the complete analysis for BSP:BLAU3
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:BLAU3 has been successfully added to your 
